Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Which antiphospholipid antibody tests are most useful?

J T Merrill1

  • 1Division of Rheumatology, St. Luke's-Roosevelt Hospital Center, New York, New York, USA. jtm5@columbia.edu

Rheumatic Diseases Clinics of North America
|September 6, 2001
PubMed
Summary

Improving antiphospholipid syndrome (APS) diagnosis and treatment faces challenges due to non-standardized tests and limited epidemiologic data. Strategic approaches can enhance the efficiency of current diagnostic tools for Hughes syndrome.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Quantifying stratosphere-troposphere transport of ozone using balloon-borne ozonesondes, radar windprofilers and trajectory models.

Atmospheric environment (Oxford, England : 1994)·2020
Same author

A double-blind, randomized, placebo-controlled, phase II trial of baricitinib for systemic lupus erythematosus: how to optimize lupus trials to examine effects on cutaneous lupus erythematosus.

The British journal of dermatology·2019
Same author

The prevalence and determinants of anti-DFS70 autoantibodies in an international inception cohort of systemic lupus erythematosus patients.

Lupus·2017
Same author

Long-Term Safety and Efficacy of Epratuzumab in the Treatment of Moderate-to- Severe Systemic Lupus Erythematosus: Results From an Open-Label Extension Study.

Arthritis care & research·2015
Same author

Efficacy and safety of subcutaneous tabalumab, a monoclonal antibody to B-cell activating factor, in patients with systemic lupus erythematosus: results from ILLUMINATE-2, a 52-week, phase III, multicentre, randomised, double-blind, placebo-controlled study.

Annals of the rheumatic diseases·2015
Same author

Genetic association of CD247 (CD3ζ) with SLE in a large-scale multiethnic study.

Genes and immunity·2015

Area of Science:

  • Rheumatology
  • Immunology
  • Clinical Epidemiology

Background:

  • Antiphospholipid syndrome (APS), also known as Hughes syndrome, is a significant autoimmune condition.
  • International efforts aim to improve APS diagnosis and treatment.
  • Current diagnostic and predictive tests for APS face limitations.

Purpose of the Study:

  • To address the lack of standardization in APS diagnosis.
  • To highlight the need for prospective and multivariate epidemiologic analysis in APS.
  • To guide strategic approaches for maximizing the utility of available APS tests.

Main Methods:

  • Review of published series on antiphospholipid syndrome.
  • Analysis of current diagnostic and predictive test capabilities.

Related Experiment Videos

  • Identification of strategic approaches for test utilization.

    • Main Results:

    • Lack of standardization and limited epidemiologic data hinder diagnostic and predictive abilities of current APS tests.
    • Existing published data offer insights for optimizing test efficiency.
    • Further research is needed for robust multivariate epidemiologic analysis.

    Conclusions:

    • Standardization of diagnostic criteria and tests is crucial for antiphospholipid syndrome.
    • Prospective, multivariate epidemiologic studies are essential for improving APS management.
    • Strategic utilization of current tests can improve clinical decision-making for Hughes syndrome patients.